VANCOUVER, BC, Jan. 19, 2022 /PRNewswire/ - Willow Biosciences
Inc. ("Willow" or the "Company")
(TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company
that manufactures pure, consistent and sustainable cannabinoids
via yeast biosynthesis, is pleased to announce the results
of its in vitro analysis and the first to be reported
topical clinical study on cannabigerol ("CBG"). In
collaboration with Signum Biosciences, Willow's
FutureGrownTM CBG, produced using its proprietary
yeast platform at multi-kilogram scale, demonstrated antioxidant,
anti-inflammatory, and skin health-boosting activity in lab assays,
and provided similar benefits when applied topically to human skin.
A single-blind clinical study in 20 healthy male and female
volunteers conducted at Princeton Consumer Research (the "Willow
Study") showed Willow's FutureGrownTM CBG
clinically reduces skin inflammation, the appearance of redness,
and improves barrier function. The results of the Willow Study were
published in Molecules, a leading
international, peer-reviewed, open access journal that can be
found here at https://www.mdpi.com/1420-3049/27/2/491/htm.
"Willow's FutureGrownTM CBG continues to exhibit
great promise as an exciting new skincare ingredient", said
Trevor Peters, Willow's President
and Chief Executive Officer. "We are excited to share the results
of our in vitro and clinical work with our stakeholders and
proud to have it published in a peer reviewed scientific journal,
the first of its kind for CBG. As the market for CBG and CBGA
continues to develop, key studies such as this help to define the
potential these ingredients have in the health and wellness
space."
The Willow Study reports that biosynthetically produced CBG
possesses a broad range of anti-inflammatory, antioxidant, and skin
protecting properties to help slow inflammation, aging, and boost
skin barrier function. Gene array analysis of CBG and cannabidiol
("CBD") applied topically to a 3D human skin model
demonstrates that CBG outperforms CBD, selectively targeting
collagen, elastin and other key skin health and hydration genes.
Moreover, in vitro studies in normal human
epidermal keratinocytes (NHEKs) and human dermal fibroblasts (HDFs)
show that CBG and CBD both possess strong antioxidant and
anti-inflammatory properties, with CBG demonstrating equal if not
better activity than CBD. Lastly, the Willow Study is the first to
report the clinical effectiveness of topically applied CBG,
demonstrating that a 0.1% CBG serum reduces inflammation, redness,
and improves the skin barrier significantly better than a
placebo.
Learn more about Willow's FutureGrownTM CBG:
www.willowbio.com/#products
Request samples of Willow's FutureGrownTM CBG:
info@willowbio.com
About Willow Biosciences Inc.
Willow is a leading biotechnology company that develops and
produces high-purity, plant derived ingredients for the consumer
care, food and beverage, and pharmaceutical markets. Willow's
FutureGrownTM biotechnology platform allows scale
production of pure, consistent, and sustainable product to benefit
both B2B and B2C customers. Willow's R&D team has a proven
track record of developing and commercializing bio-based
manufacturing processes and products for both the consumer and
pharmaceutical industries.
Forward-Looking Statements
This news release may include forward-looking statements
including opinions, assumptions, estimates and the Company's
assessment of future plans and operations, and, more particularly,
statements concerning: the results of the Willow Study, including
the clinical benefits of CBG for skincare; Willow's
FutureGrownTM CBG; and the business plan of the
Company, generally, including cannabinoid research and production.
When used in this news release, the words "will," "anticipate,"
"believe," "estimate," "expect," "intent," "may," "project,"
"should," and similar expressions are intended to be among the
statements that identify forward-looking statements. The
forward-looking statements are founded on the basis of expectations
and assumptions made by the Company and, with respect to the Willow
Study, Signum Biosciences which include, but are not limited to:
the expectations and assumptions set forth in the published results
of the Willow Study; the success of Willow's strategic
partnerships, including the development of future strategic
partnerships; the financial strength of the Company; the ability of
the Company to fund its business plan using cash on hand and
existing resources; the market for Willow's products; the ability
of the Company to obtain and retain applicable licences; the
ability of the Company to obtain suitable manufacturing partners
and other strategic relationships; and the successful
implementation of Willow's commercialization and production
strategy, generally. Forward-looking statements are subject to a
wide range of risks and uncertainties, and although the Company
believes that the expectations represented by such forward-looking
statements are reasonable, there can be no assurance that such
expectations will be realized. Any number of important factors
could cause actual results to differ materially from those in the
forward-looking statements including, but not limited to, risks
associated with: the cannabinoid industry in general; the success
of the Company's research and development strategies; infringement
on intellectual property; failure to benefit from partnerships or
successfully integrate acquisitions; actions and initiatives of
federal and provincial governments and changes to government
policies and the execution and impact of these actions, initiatives
and policies; import/export and research restrictions for
cannabinoid-based operations; the size of the medical-use and
adult-use cannabinoid market; competition from other industry
participants; adverse U.S., Canadian and global economic
conditions; adverse global events and public-health crises,
including the current COVID-19 outbreak; failure to comply with
certain regulations; departure of key management personnel or
inability to attract and retain talent; and other factors more
fully described from time to time in the reports and filings made
by the Company with securities regulatory authorities. Please refer
to the Company's most recent annual information form and
management's discussion and analysis for additional risk factors
relating to Willow, which can be accessed either on Willow's
website at www.willowbio.com or under the Company's profile on
www.sedar.com.
The forward-looking statements contained in this news release
are made as of the date hereof and the Company does not undertake
any obligation to update publicly or to revise any of the included
forward-looking statements, except as required by applicable law.
The forward-looking statements contained herein are expressly
qualified by this cautionary statement.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-publishes-the-first-peer-reviewed-article-demonstrating-the-clinical-benefit-of-cbg-for-skincare-301463564.html
SOURCE Willow Biosciences Inc.